SCHEMBL4153134

SCHEMBL4153134

Cn1c(C(=O)N[C@H]2CCCN(c3ccccc3)C2)cc2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNA7 P36544 1/20 0.52
PPARA Q07869 5/20 0.49
PPARD Q03181 4/20 0.49
CNR1 P21554 1/20 0.49
CNR2 P34972 1/20 0.47
MCL1 Q07820 1/20 0.47
USP30 Q70CQ3 1/20 0.47
KDM4E B2RXH2 3/20 0.46
HSD17B10 Q99714 3/20 0.46
ALDH1A1 P00352 2/20 0.46
HPGD P15428 1/20 0.46
PPARG P37231 2/20 0.46
F10 P00742 1/20 0.46
POLB P06746 1/20 0.45
HTR1A P08908 1/20 0.45
DRD2 P14416 1/20 0.45
HTR2A P28223 1/20 0.45
HTR2C P28335 1/20 0.45
DRD3 P35462 1/20 0.45
MEN1 O00255 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2276515 0.81 CHRNA7 (0.61) CHRNA7CNR2MCL1KDM4EHSD17B10
SCHEMBL4011287 0.76 CNR1 (0.64) PPARAPPARDCNR1USP30ALDH1A1
SCHEMBL4011282 0.76 CNR1 (0.64) PPARAPPARDCNR1USP30ALDH1A1
SCHEMBL14859926 0.76 CNR1 (0.64) PPARAPPARDCNR1USP30ALDH1A1
SCHEMBL19701326 0.76 CHRNA7 (0.56) CHRNA7CNR2MCL1KDM4EHSD17B10
SCHEMBL21489902 0.76 CHRNA7 (0.56) CHRNA7CNR2MCL1KDM4EHSD17B10
SCHEMBL4130958 0.75 CCKBR (0.54) CHRNA7CNR1KDM4EHSD17B10ALDH1A1
SCHEMBL4010838 0.75 NPC1 (0.63) PPARAPPARDCNR1CNR2ALDH1A1
SCHEMBL4010842 0.75 NPC1 (0.63) PPARAPPARDCNR1CNR2ALDH1A1
SCHEMBL24587600 0.74 CHRNA7 (0.50) CHRNA7CNR1CNR2USP30F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CHRNA7 2508/4885PPARA 340/4885PPARD 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.